COSTA, FEDERICA
 Distribuzione geografica
Continente #
NA - Nord America 858
EU - Europa 772
AS - Asia 377
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.024
Nazione #
US - Stati Uniti d'America 848
CN - Cina 280
SE - Svezia 193
IE - Irlanda 187
IT - Italia 184
DE - Germania 66
FI - Finlandia 59
TR - Turchia 53
SG - Singapore 30
AT - Austria 21
CZ - Repubblica Ceca 14
FR - Francia 11
CI - Costa d'Avorio 10
RO - Romania 10
CA - Canada 9
IN - India 9
BE - Belgio 6
GB - Regno Unito 6
NL - Olanda 6
ES - Italia 4
EU - Europa 2
HK - Hong Kong 2
KH - Cambogia 2
NG - Nigeria 2
SC - Seychelles 2
SM - San Marino 2
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
EG - Egitto 1
IR - Iran 1
MX - Messico 1
Totale 2.024
Città #
Chandler 218
Dublin 187
Parma 92
Ann Arbor 74
Ashburn 71
Shanghai 56
Dearborn 54
New York 49
Izmir 38
Nanjing 36
Beijing 35
Princeton 32
Shenyang 23
Vienna 21
Wilmington 20
Helsinki 18
Bremen 13
Hebei 13
Jinan 13
Kocaeli 13
Kunming 13
Nanchang 13
Brno 12
Singapore 11
Abidjan 10
Jiaxing 10
Milan 10
Munich 10
San Mateo 10
Redmond 9
Boardman 8
Focsani 8
Tianjin 8
Los Angeles 7
Woodbridge 7
Zhengzhou 7
Brussels 6
Changsha 6
Hangzhou 6
Hefei 6
Modena 6
Toronto 6
Fairfield 5
Palermo 5
Chongqing 4
Dallas 4
Des Moines 4
Houston 4
Madrid 4
Norwalk 4
Rio Saliceto 4
Seattle 4
Torino 4
Ahmedabad 3
Düsseldorf 3
Gorgonzola 3
Redwood City 3
Reggio Emilia 3
Taizhou 3
Washington 3
Bologna 2
Cornaredo 2
Deiva Marina 2
Guangzhou 2
Haikou 2
Hong Kong 2
Lagos 2
Mestre 2
Ottawa 2
Phnom Penh 2
Pune 2
Rho 2
Rockville 2
Rome 2
Segrate 2
Tampa 2
Turku 2
Vignola 2
Xian 2
Ankara 1
Atlanta 1
Augusta 1
Borås 1
Bucharest 1
Buffalo 1
Cairo 1
Castelfranci 1
Castelfranco Emilia 1
Charlotte 1
Chengdu 1
Chicago 1
Denver 1
Edinburgh 1
Frankfurt am Main 1
Fremont 1
Jacksonville 1
Jinhua 1
Lanzhou 1
Las Vegas 1
Lausanne 1
Totale 1.391
Nome #
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 99
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 97
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 81
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 79
Possible targets to treat myeloma-related osteoclastogenesis 78
Oncolytic virotherapy and microenvironment in multiple myeloma 77
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 76
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 76
The Proteasome and Myeloma-Associated Bone Disease 75
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 73
Improved scaffold biocompatibility through anti-Fibronectin aptamer functionalization 71
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 69
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 66
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 66
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 65
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 63
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 63
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. 63
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 63
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 61
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 60
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 60
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 58
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 56
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 56
CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents 52
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 51
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 50
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 48
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 47
CD38: A target for immunotherapeutic approaches in multiple myeloma 42
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 37
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 21
Totale 2.099
Categoria #
all - tutte 8.537
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.537


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020226 0 34 5 7 8 47 37 9 31 32 11 5
2020/2021198 13 4 4 4 37 6 9 15 40 28 9 29
2021/2022164 5 5 10 14 3 0 28 10 14 11 8 56
2022/2023805 90 93 64 70 63 86 29 49 223 7 22 9
2023/2024333 16 30 10 6 23 104 36 17 9 14 11 57
2024/202519 15 4 0 0 0 0 0 0 0 0 0 0
Totale 2.099